A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).

Authors:
  • APA. T. Phan
    A. T. Phan
  • JYJ. C. Yao
    J. C. Yao
  • DFD. R. Fogelman
    D. R. Fogelman
  • KHK. R. Hess
    K. R. Hess
  • CNC. S. Ng
    C. S. Ng
  • SBS. A. Bullock
    S. A. Bullock
  • PMP. Malinowski
    P. Malinowski
  • ERE. Regan
    E. Regan
  • MKM. Kulke
    M. Kulke

Abstract
4001 Background: Current treatments options for advanced LGNEC are limited. Vascular endothelial growth factor (VEGF) pathway inhibitors, including bevacizumab, sorafenib,and sunitinib have shown preliminary evidence of activity in NEC. Additionally, octreotide has cytostatic activity in NEC. Pazopanib is a selective, orally available, small molecule inhibitor of the VEGFR-1, -2, and -3, PDGF-α, PDGF-β, and c-kit tyrosine kinases. We performed a prospective study of pazopanib administered in combination with octreotide in pts with advanced LGNEC. Methods: Pts with either carcinoid (C) or pancreatic NET (PNET) on a stable dose of depot octreotide (LAR) for ≥ 2 months were enrolled at 2 institutions (MDACC, DFCI). Pts with prior VEGF pathway inhibitor treatment were excluded. Pts received pazopanib 800mg PO daily in combination with LAR at their prior dose level. A 2-cohort (C, PNET), 2-stage design was employed, with early stopping if no RECIST-defined response was observed among the first 20 evaluable pts...